

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangdong True Health Medical Technology Development Co., Ltd.

廣東真健康醫療科技開發股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02697)

Voluntary Announcement on Significant Progress in Research on Extracorporeal Liver Perfusion Support Therapy Using an Organ Perfusion System

This announcement is made voluntarily by Guangdong True Health Medical Technology Development Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide shareholders of the Company and potential investors with the latest business developments of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, leveraging its self-developed organ perfusion system, the Company has successfully completed preclinical trials involving six cases of cross-organ perfusion support therapy in an ex vivo model of genetically edited porcine liver for non-human primate acute liver failure. In accordance with the relevant requirements of State Council Order No. 818 regarding the Guidelines for the Record-Filing of Clinical Research on New Xenotransplantation Technologies in the Clinical Research and Clinical Translation of New Biomedical Technologies, the research group, in collaboration with Yunnan Agricultural University, The First People's Hospital of Kunming, and The First Affiliated Hospital of Anhui Medical University, has set a record of stable liver function perfusion support therapy lasting up to 144 hours, with all six cases exceeding 72 hours. This achievement represents the first global demonstration of prolonged efficacy validation for this technology.

Experimental results demonstrated that during the study period, the animals exhibited stable physiological parameters, continuous secretion of donor bile, and overall stability of key biochemical indicators, effectively compensating for

hepatic physiological functions. Concurrently, immune rejection reactions remained controllable, with no occurrence of hyperacute or acute rejection-related injuries, thereby successfully overcoming critical technical challenges in xenogeneic liver transplantation.

In this study, leveraging the organ perfusion system independently developed by True Health Medical Technology, and integrating the 8-gene-edited medical donor pig liver developed by Yunnan Agricultural University, the Company has established a safe and stable extracorporeal liver perfusion support therapy platform. The System constitutes a modular organ medical equipment platform, featuring a universal core host unit paired with interchangeable specialized pipelines, organ chambers, perfusion solutions, and other consumables and configuration modules. Without the need to replace the core host unit, this platform enables research and applications in normothermic perfusion preservation and extracorporeal life support for multiple organs—including the liver, kidney, heart, and lung—thereby demonstrating significant technical potential for extending from organ perfusion preservation to extracorporeal perfusion support therapy research.

Liver failure is a serious disease associated with a high risk of mortality. Existing artificial liver support technologies still exhibit limitations in fully replacing the complex physiological functions of the liver, whereas liver transplantation is constrained by factors such as the availability of donor livers, the patient's clinical condition, and the optimal timing for transplantation. The gene-edited pig liver extracorporeal perfusion support technology aims to explore the use of an extracorporeal perfusion system to connect a biologically viable ex vivo liver, thereby providing potential liver function support and securing critical time for patients with severe liver failure to either restore liver function or undergo liver transplantation.

Research on related technologies leveraging organ perfusion systems holds promise for future exploration and application in a variety of diseases associated with severe hepatic dysfunction and in diverse clinical settings, including but not limited to: acute liver failure, subacute liver failure, acute-on-chronic liver failure, severe hepatic decompensation and related critical liver diseases, critically ill patients in the waiting period for liver transplantation, and severe hepatic dysfunction following liver transplantation. Currently, these applications remain in the exploratory research phase and have not yet been approved as clinical indications.

China has a vast patient population suffering from chronic liver disease, and novel ex vivo liver function perfusion support technologies hold promising clinical application prospects worthy of further investigation. This study

provides a scientific foundation for subsequent technical optimization, system performance validation, and the initiation of clinical trials. The Company will continue to advance the technical development and applied research of organ perfusion systems, refine research data, evaluate safety and efficacy, and collaborate with healthcare institutions and research institutes to explore the feasibility of clinical translation of this technology.

The Board hereby reminds shareholders of the Company and potential investors that, the six trials described in this announcement are preclinical studies; their completion does not indicate that the relevant technologies have demonstrated safety and efficacy in human beings, nor does it mean that the relevant products have obtained medical device registration certificates or clinical application approvals. There remain uncertainties regarding the relevant potential indications, clinical translation pathways, and commercialization prospects. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Guangdong True Health Medical Technology Development Co., Ltd.
Cheong Hou Iam
Chairperson and Executive Director

Hong Kong, 12 October 2026

As at the date of this announcement, the executive Directors are Ms. Cheong Hou Iam (Chairperson), Ms. Chen Miaoping and Ms. Guo Jian and the independent non-executive Directors are Dr. Liu Lianggang, Mr. Ng Kun Seng Chris and Mr. Ma Jianming.